Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL770166 | 0.95 | ALDH1A1 (0.44) | ALDH1A1MEN1KMT2AGAAPKM | |
| SCHEMBL769695 | 0.88 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2AGAAPKM | |
| SCHEMBL770656 | 0.81 | MGLL (0.38) | ALDH1A1MEN1KMT2AGAAPKM | |
| SCHEMBL1334284 | 0.78 | HDAC3 (0.50) | ALDH1A1MEN1KMT2AGAAMGLL | |
| SCHEMBL10296061 | 0.78 | ALDH1A1 (0.49) | ALDH1A1MEN1KMT2AGAAPKM | |
| SCHEMBL11102866 | 0.76 | MGLL (0.50) | MGLLS1PR2S1PR1S1PR3 | |
| SCHEMBL7999163 | 0.75 | ALDH1A1 (0.46) | ALDH1A1GAAKDM4EMAPTL3MBTL1 | |
| SCHEMBL3299700 | 0.75 | GAA (0.44) | ALDH1A1GAAKDM4EMAPTL3MBTL1 | |
| SCHEMBL769729 | 0.75 | NFKB1 (0.37) | ALDH1A1MEN1KMT2AGAAPKM | |
| SCHEMBL4774245 | 0.75 | TSHR (0.48) | ALDH1A1MEN1KMT2AGAAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9926274-B2 | Process for producing substituted methylamine compound and triazine derivative | NIPPON SODA CO., LTD. (JP) | 2018-03-27 | — | — | US | disclosed |
| EP-2650283-B1 | Process for producing substituted methylamine compound and triazine derivative | NIPPON SODA CO (JP) | 2017-06-07 | — | — | EP | disclosed |
| EP-2650282-B1 | Process for producing substituted methylamine compound and triazine derivative | NIPPON SODA CO (JP) | 2017-06-07 | — | — | EP | disclosed |
| US-20150141653-A1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | NIPPON SODA CO (JP) | 2015-05-21 | — | — | US | disclosed |
| US-9000156-B2 | Process for producing substituted methylamine compound and triazine derivative | NIPPON SODA CO., LTD. (JP) | 2015-04-07 | — | — | US | disclosed |
| US-20140323724-A1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | NIPPON SODA CO (JP) | 2014-10-30 | — | — | US | disclosed |
| EP-2141149-B1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | NIPPON SODA CO (JP) | 2014-10-29 | — | — | EP | disclosed |
| EP-2650282-A1 | Process for producing substituted methylamine compound and triazine derivative | NIPPON SODA CO., LTD. (JP) | 2013-10-16 | — | — | EP | disclosed |
| EP-2650283-A1 | Process for producing substituted methylamine compound and triazine derivative | NIPPON SODA CO., LTD. (JP) | 2013-10-16 | — | — | EP | disclosed |
| US-20120071656-A1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | NIPPON SODA CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20100121054-A1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | NIPPON SODA CO., LTD. (JP) | 2010-05-13 | — | — | US | disclosed |
| EP-2141149-A1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | Nippon Soda Co., Ltd. (JP) | 2010-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071656-A1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | INMT, BHMT2, HNMT | ALDH1A1 3841/4885MEN1 1617/4885KMT2A 72/4885 |
| US-20140323724-A1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | INMT, BHMT2, HNMT | ALDH1A1 3841/4885MEN1 1617/4885KMT2A 72/4885 |
| US-20150141653-A1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | INMT, BHMT2, HNMT | ALDH1A1 3841/4885MEN1 1617/4885KMT2A 72/4885 |
| US-20100121054-A1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | INMT, BHMT2, HNMT | ALDH1A1 3865/4885MEN1 1420/4885KMT2A 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.